Indeed, the decision to order the FDG-PET/CT scan was made by the treating oncologist and was based on medical and non‐medical considerations, including the unavailability of other more specific PET radiotracers for prostate cancer (such as choline or PSMA). This evidence concerns the gene FOLH1 and prostate carcinoma.